Cytarabine is a medication used in the management and treatment of leukemias and lymphomas. It belongs to the antimetabolic group of medications. This activity reviews the indications, action, and contraindications for cytarabine as a valuable agent in treating acute myeloid leukemia (and other leukemias). This activity will highlight the mechanism of action, adverse event profile, and other key factors (e.g., off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, relevant interactions) pertinent for members of the healthcare team in the treatment of patients with leukemia and related conditions.

**Objectives:**
- Identify the mechanism of action of cytarabine.
- Describe the potential adverse effects of cytarabine.
- Review the appropriate monitoring for patients receiving therapy with cytarabine.
- Summarize interprofessional team strategies for improving care coordination for patient safety in cases of cytarabine overdose and improve outcomes.